HELM INTELLIGENCELLY
Preparing your analysis.
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Working on your request
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Investors should consider the company's strong growth metrics alongside the competitive landscape when evaluating Eli Lilly's stock.
Eli Lilly & Co has a market capitalization of $1.03T and a current stock price of $1,143.40, reflecting a change of +2.55% from the previous close of $1,114.98. The company exhibits a P/E ratio of 49.82, an EPS growth year-over-year of 95.99%, and a revenue growth year-over-year of 44.70%. The stock has a 52-week high of $1,293 and a low of $712.
Proponents of Eli Lilly cite the impressive EPS growth of 95.99% and revenue growth of 44.70% as indicators of strong business performance. Additionally, its high return on equity (ROE) of 77.78% suggests effective management and profitability.
Critics point to the high P/E ratio of 49.82 as a potential indicator of overvaluation, especially in a competitive market. Recent headlines indicate concerns about competition from other firms like Novo Nordisk, which may impact future growth prospects.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Eli Lilly & Co has a market capitalization of $1.03T and a current stock price of $1,143.40, reflecting a change of +2.55% from the previous close of $1,114.98. The company exhibits a P/E ratio of 49.82, an EPS growth year-over-year of 95.99%, and a revenue growth year-over-year of 44.70%. The stock has a 52-week high of $1,293 and a low of $712.
Critics point to the high P/E ratio of 49.82 as a potential indicator of overvaluation, especially in a competitive market. Recent headlines indicate concerns about competition from other firms like Novo Nordisk, which may impact future growth prospects.
Proponents of Eli Lilly cite the impressive EPS growth of 95.99% and revenue growth of 44.70% as indicators of strong business performance. Additionally, its high return on equity (ROE) of 77.78% suggests effective management and profitability.
Proponents of Eli Lilly cite the impressive EPS growth of 95.99% and revenue growth of 44.70% as indicators of strong business performance. Additionally, its high return on equity (ROE) of 77.78% suggests effective management and profitability. Critics point to the high P/E ratio of 49.82 as a potential indicator of overvaluation, especially in a competitive market. Recent headlines indicate concerns about competition from other firms like Novo Nordisk, which may impact future growth prospects.
Eli Lilly & Co has a market capitalization of $1.03T and a current stock price of $1,143.40, reflecting a change of +2.55% from the previous close of $1,114.98. The company exhibits a P/E ratio of 49.82, an EPS growth year-over-year of 95.99%, and a revenue growth year-over-year of 44.70%. The stock has a 52-week high of $1,293 and a low of $712.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for LLY at helmterminal.dev/analyze/LLY, updated continuously during US market hours. No signup required.